's () Jonathan Farr, Chief Clinical Officer, talks to Proactive London's Katie Pilbeam about their latest findings in regard to resistant cancers.
The firm recently announced to their investors that it had demonstrated superiority of its LIGHT technology in 'biologically enhanced particle therapy' to treat these resistant cancers.
Farr explains, these cancers are responsible for most relapses and one of the major causes of death in cancer.
Due to the their LIGHT system and its smaller beam size compared to legacy systems and its ability to deposit a greater level of radiation damage in a micro-target volume, it is suited to contribute to the development of personalised medicines.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...
FOR OUR FULL DISCLAIMER CLICK HERE